Zobrazeno 1 - 10
of 47 700
pro vyhledávání: '"Metabolic clearance rate"'
Autor:
Nagar S; Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania korzekwa@temple.edu swati.nagar@temple.edu., Parise R; Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania., Korzekwa K; Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania korzekwa@temple.edu swati.nagar@temple.edu.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Sep 16; Vol. 52 (10), pp. 1060-1072. Date of Electronic Publication: 2024 Sep 16.
Autor:
Schulz Pauly JA; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Sande E; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Feng M; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Wang YT; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Stresser DM; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois., Kalvass JC; Quantitative, Translational, and ADME Sciences, Abbvie Inc., North Chicago, Illinois j.kalvass@abbvie.com.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Sep 16; Vol. 52 (10), pp. 1048-1059. Date of Electronic Publication: 2024 Sep 16.
Autor:
Poulin P; Consultant Patrick Poulin Inc., Québec City, Québec, Canada; School of Public Health, Université de Montréal, Montréal, Québec, Canada. Electronic address: patrick-poulin@videotron.ca.
Publikováno v:
Journal of pharmaceutical sciences [J Pharm Sci] 2024 Aug; Vol. 113 (8), pp. 2641-2650. Date of Electronic Publication: 2024 May 24.
Autor:
Pang KS; Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada (K.S.P., W.I.L.) and Department of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands (G.J.M.) ks.pang@utoronto.ca., Lu WI; Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada (K.S.P., W.I.L.) and Department of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands (G.J.M.)., Mulder GJ; Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada (K.S.P., W.I.L.) and Department of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands (G.J.M.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Jul 16; Vol. 52 (8), pp. 919-931. Date of Electronic Publication: 2024 Jul 16.
Autor:
Kukla DA; Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois., Belair DG; Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois., Stresser DM; Quantitative, Translational, and ADME Sciences, AbbVie Inc., North Chicago, Illinois david.stresser@abbvie.com.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Jul 16; Vol. 52 (8), pp. 797-812. Date of Electronic Publication: 2024 Jul 16.
Autor:
Weiss M; Department of Pharmacology, Martin Luther University Halle-Wittenberg, Magdeburger Straße 20 (Saale), 06112, Halle, Germany. michael.weiss@medizin.uni-halle.de.
Publikováno v:
Pharmaceutical research [Pharm Res] 2024 Jul; Vol. 41 (7), pp. 1391-1400. Date of Electronic Publication: 2024 Jul 09.
Comparison of Human Long-Term Liver Models for Clearance Prediction of Slowly Metabolized Compounds.
Autor:
Preiss LC; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.)., Georgi K; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.)., Lauschke VM; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.)., Petersson C; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (L.C.P., V.M.L.); Department of Drug Metabolism and Pharmacokinetics (DMPK), The Healthcare Business of Merck KGaA, Darmstadt, Germany (L.C.P., K.G., C.P.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (V.M.L.); and University of Tuebingen, Tuebingen, Germany (V.M.L.) carl.petersson@merckgroup.com.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 May 16; Vol. 52 (6), pp. 539-547. Date of Electronic Publication: 2024 May 16.
Autor:
Chen, Yue1 (AUTHOR), Zhang, Kang-xi2 (AUTHOR), Liu, Hui2,3 (AUTHOR), Zhu, Yue1 (AUTHOR), Bu, Qing-yun2,3 (AUTHOR), Song, Shu-xia2 (AUTHOR), Li, Ya-chun2 (AUTHOR), Zou, Hong4 (AUTHOR) hzhou01@sinh.ac.cn, You, Xiao-yan1,2,3 (AUTHOR) youxy@tib.cas.cn, Zhao, Guo-ping1,4,5 (AUTHOR) gpzhao@sibs.ac.cn
Publikováno v:
Scientific Reports. 9/10/2024, Vol. 14 Issue 1, p1-12. 12p.
Autor:
Zheng J; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Lu B; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Carr G; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Mwangi J; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Wang K; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Hao J; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Staiger KM; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Kozon N; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Murray BP; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Bashir M; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Gohdes MA; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Tse WC; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Schroeder S; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Graupe M; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Link JO; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Yoon J; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Chiu A; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Rowe W; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Smith BJ; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.)., Subramanian R; Gilead Sciences, Inc., Foster City, California (J.Z., B.L., G.C., J.M., K.W., J.H., K.M.S., N.K., B.P.M., W.C.T., S.S., M.G., J.O.L., J.Y., A.C., W.R., B.J.S., R.S.); and Labcorp Early Development Laboratories Inc., Madison, Wisconsin (M.B., M.A.G.) Raju.Subramanian@gilead.com.
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2024 Sep 18; Vol. 391 (1), pp. 91-103. Date of Electronic Publication: 2024 Sep 18.
Autor:
Bauman JN; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.) jonathan.bauman@pfizer.com., Doran AC; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Gualtieri GM; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Hee B; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Strelevitz T; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Cerny MA; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Banfield C; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Plotka A; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Wang X; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Purohit VS; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.)., Dowty ME; Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., Cambridge, Massachusetts (M.E.D.) andGroton, Connecticut (J.N.B., A.C.D., G.M.G., B.H., T.S., M.A.C.); Clinical Pharmacology, Pfizer, Inc., Groton, Connecticut (C.B., X.W., V.S.P.); Biostatistics, Pfizer, Inc., Collegeville, Pennsylvania (A.P.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Sep 16; Vol. 52 (10), pp. 1124-1136. Date of Electronic Publication: 2024 Sep 16.